Browse allOrano MedCRO / CDMO · FrancePeptide synthesis, bioconjugation and analytical testing.Request a quoteAsk about this companyWebsite (opens in a new tab)What they doDiscovery & researchPeptide synthesisPreclinicalPreclinical developmentDevelopment & CMCBioconjugationTesting & analysisAnalytical testingClinicalClinical development servicesFrom their websiteAreva med’s second production facility on schedule to open in 2nd quarter of 2016GMP production (opens in a new tab)Site-specific bioconjugation (opens in a new tab)Peptide conjugate synthesis (opens in a new tab)Pipeline212 Pb manufacturing (opens in a new tab)212 Pb distribution (opens in a new tab)Targeted alpha therapyRadiolabeling (opens in a new tab)Alpha radioimmunotherapy (opens in a new tab)Chemical production process (opens in a new tab)Industrial platformExtraction and purification (opens in a new tab)212 Pb production (opens in a new tab)Radioligand therapy production (opens in a new tab)Our ambitionAntibody site specific conjugation (opens in a new tab)Orano med inaugurates expansion of its u.s. research and development center in texasIn vivo studies (opens in a new tab)CMC studies (opens in a new tab)GMP production capacity (opens in a new tab)TechnologyPreclinical facilities (opens in a new tab)Chelating-agent design (opens in a new tab)Quality & certificationsGMP standards (opens in a new tab)GMP (opens in a new tab)